๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study

โœ Scribed by Kochi, Mitsugu; Akiyama, Yuji; Aoki, Tatsuya; Hagiwara, Ken; Takahashi, Takao; Hironaka, Katsuji; Teranishi, Futoshi; Osuka, Fumihiko; Takeuchi, Masahiro; Fujii, Masashi; Nakajima, Toshifusa

Book ID
121611397
Publisher
Springer
Year
2013
Tongue
English
Weight
453 KB
Volume
72
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

FOLFIRI plus cetuximab versus FOLFIRI pl
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
โœ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa ๐Ÿ“‚ Article ๐Ÿ“… 2014 ๐Ÿ› Lancet Publishing Group ๐ŸŒ English โš– 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow